Table 3.
Adjusted estimates of risk reduction of the onset of each deterioration assessment for patients taking enzalutamide vs. placebo (inverted hazard ratios [HR] and 95% confidence intervals [CI])
| Deterioration events | Adjusted 1/HR | 95% CI | P value |
|---|---|---|---|
| Any worsening from baseline full health (EQ index = 1) | 0.52 | 0.42–0.65 | <0.0001 |
| Any decrease in EQ-5D index | 0.53 | 0.48–0.61 | <0.0001 |
| Any decrease in EQ-5D VAS | 0.62 | 0.55–0.70 | <0.0001 |
| “Worsening” on PCHC | 0.76 | 0.65–0.88 | 0.0003 |
| Worsening in EQ-5D dimensions | |||
| Mobility | 0.87 | 0.68–1.10 | 0.2357 |
| Self-care | 0.60 | 0.43–0.83 | 0.0019 |
| Usual Activities | 0.85 | 0.70–1.03 | 0.1066 |
| Pain/Discomfort | 0.57 | 0.47–0.68 | <0.0001 |
| Anxiety/Depression | 0.66 | 0.53–0.83 | 0.0003 |
PCHC Paretian Classification of Health Change, VAS visual analogue scale
Relative risk reduction and 95% CIs from Cox proportional hazards models adjusted by the following baseline factors: age, fatigue score, pain score, geographic region, and baseline EQ-5D index or corresponding dimension value